BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37407972)

  • 1. Treatment compliance among adult cervical cancer patients receiving care at Uganda cancer institute, Uganda: a retrospective data review.
    Najjemba JI; Ndagire R; Mulamira P; Kibudde S; Lwanira CN
    BMC Cancer; 2023 Jul; 23(1):631. PubMed ID: 37407972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.
    Chen SW; Liang JA; Yang SN; Ko HL; Lin FJ
    Radiother Oncol; 2003 Apr; 67(1):69-76. PubMed ID: 12758242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
    Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
    Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer.
    Zhang M; Xu HD; Pan SD; Lin S; Yue JH; Liu JR
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):966-71. PubMed ID: 22138462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
    Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
    BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
    Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
    Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes following conventional external beam radiotherapy boost in Japanese patients with cervical cancer who are ineligible for intracavitary brachytherapy.
    Ito K; Shimizuguchi T; Karasawa K
    Jpn J Clin Oncol; 2019 Mar; 49(3):270-275. PubMed ID: 30576504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
    Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
    Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose-rate brachytherapy for elderly patients with uterine cervical cancer.
    Chen SW; Liang JA; Yang SN; Lin FJ
    Jpn J Clin Oncol; 2003 May; 33(5):221-8. PubMed ID: 12865465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
    Serkies K; Jassem J
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulsed low dose rate brachytherapy for uterine cervix carcinoma.
    Rogers CL; Freel JH; Speiser BL
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):95-100. PubMed ID: 9989519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI-guided high-dose-rate intracavitary brachytherapy for treatment of cervical cancer: the University of Pittsburgh experience.
    Gill BS; Kim H; Houser CJ; Kelley JL; Sukumvanich P; Edwards RP; Comerci JT; Olawaiye AB; Huang M; Courtney-Brooks M; Beriwal S
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):540-7. PubMed ID: 25680598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
    Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
    Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer.
    Martínez-Monge R; Gaztañaga M; Aramendía JM; Cambeiro M; Arbea L; Espinós J; Aristu JJ; Jurado M
    Int J Gynecol Cancer; 2010 Jan; 20(1):133-40. PubMed ID: 20130514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of 6 fractions of 5.3 Gray HDR brachytherapy in combination with external beam radiotherapy for treatment of cervical cancer.
    Koh WY; Lim K; Tey J; Lee KM; Lim GH; Choo BA
    Gynecol Oncol; 2013 Oct; 131(1):93-8. PubMed ID: 23906655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study.
    Cihoric N; Tsikkinis A; Vlaskou Badra E; Glatzer M; Novak U; Scherz A; Shelan M; Soldatovic I; Yojena CKK; Aebersold DM; Lössl K
    Radiat Oncol; 2017 Dec; 12(1):202. PubMed ID: 29273076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule.
    Toita T; Kakinohana Y; Ogawa K; Adachi G; Moromizato H; Nagai Y; Maehama T; Sakumoto K; Kanazawa K; Murayama S
    Int J Radiat Oncol Biol Phys; 2003 Aug; 56(5):1344-53. PubMed ID: 12873679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of the American Brachytherapy Society guidelines for the use of high-dose rate brachytherapy in the treatment of cervical carcinoma: is 45-50.4 Gy radiochemotherapy plus 31.8 Gy in six fractions high-dose rate brachytherapy tolerable?
    Shakespeare TP; Lim KH; Lee KM; Back MF; Mukherjee R; Lu JD;
    Int J Gynecol Cancer; 2006; 16(1):277-82. PubMed ID: 16445645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment results of high-dose-rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens.
    Wong FC; Tung SY; Leung TW; Sze WK; Wong VY; Lui CM; Yuen KK; O SK
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1254-64. PubMed ID: 12654435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.